title: Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity.
abstract: The E3 ubiquitin ligase Cbl-b is a negative regulator of TCR signaling that: 1) sets the activation threshold for T cells; 2) is induced in anergic T cells; and 3) protects against autoimmunity. However, the role of Cbl-b in regulating CD8 T cell activation and functions during physiological T cell responses has not been systematically examined. Using the lymphocytic choriomeningitis virus infection model, we show that Cbl-b deficiency did not significantly affect the clonal expansion of virus-specific CD8 T cells. However, Cbl-b deficiency not only increased the steady-state cell surface expression levels of TCR and CD8 but also reduced Ag-induced down-modulation of cell surface TCR expression by effector CD8 T cells. Diminished Ag-stimulated TCR down-modulation and sustained Ag receptor signaling induced by Cbl-b deficiency markedly augmented IFN-gamma production, which is known to require substantial TCR occupancy. By contrast, Cbl-b deficiency minimally affected cell-mediated cytotoxicity, which requires limited engagement of TCRs. Surprisingly, despite elevated expression of CD8 and reduced Ag-induced TCR down-modulation, the functional avidity of Cbl-b-deficient effector CD8 T cells was comparable to that of wild-type effectors. Collectively, these data not only show that Cbl-b-imposed constraint on TCR signaling has differential effects on various facets of CD8 T cell response but also suggest that Cbl-b might mitigate tissue injury induced by the overproduction of IFN-gamma by CD8 T cells. These findings have implications in the development of therapies to bolster CD8 T cell function during viral infections or suppress T cell-mediated immunopathology.
authors.affiliation: Department of Pathobiological Sciences, University of Wisconsin, Madison, WI 53706, USA.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Shamim
authors.forename: Som G
authors.initials: SG
authors.lastname: Nanjappa
authors.forename: Anju
authors.initials: A
authors.lastname: Singh
authors.forename: Erin Hemmila
authors.initials: EH
authors.lastname: Plisch
authors.forename: Scott E
authors.initials: SE
authors.lastname: LeBlanc
authors.forename: Jane
authors.initials: J
authors.lastname: Walent
authors.forename: John
authors.initials: J
authors.lastname: Svaren
authors.forename: Christine
authors.initials: C
authors.lastname: Seroogy
authors.forename: M
authors.initials: M
authors.lastname: Suresh
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis / Q000172:deficiency / Q000502:physiology*; D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology*; D016827:CD8 Antigens / Q000096:biosynthesis / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000821:virology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D007371:Interferon-gamma / Q000096:biosynthesis*; D008216:Lymphocytic Choriomeningitis / Q000276:immunology / Q000821:virology; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D010455:Peptides / Q000494:pharmacology; D050721:Proto-Oncogene Proteins c-cbl / Q000096:biosynthesis / Q000172:deficiency / Q000502:physiology*; D011948:Receptors, Antigen, T-Cell / Q000096:biosynthesis / Q000378:metabolism*; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000956:Antigens, Viral; D016827:CD8 Antigens; C118387:Cblb protein, mouse; D018984:Epitopes, T-Lymphocyte; D010455:Peptides; D011948:Receptors, Antigen, T-Cell; D007371:Interferon-gamma; D050721:Proto-Oncogene Proteins c-cbl